Skip to main content
Top
Published in: Infection 2/2011

01-04-2011 | Clinical and Epidemiological Study

Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption

Authors: S. Bagaglio, G. Bianchi, A. Danise, L. Porrino, C. Uberti-Foppa, A. Lazzarin, A. Castagna, G. Morsica

Published in: Infection | Issue 2/2011

Login to get access

Abstract

Background and objective

The prevalence and clinical significance of overt hepatitis B (OHB) in human immunodeficiency virus (HIV)-infected individuals and the effect of HAART on this cryptic infection remain controversial. We have investigated the potential effect of the interruption and subsequent re-introduction of highly active antiretroviral therapy (HAART) on the frequency and dynamics of OHB in HIV-infected individuals.

Study design

This pilot study involved 29 HIV-infected individuals who tested positive for HB anti-core antibodies in the absence of surface antigen during a 100-week period (48-week-long interruption of HAART or lamivudine monotherapy plus 52 weeks of follow-up prior to HAART resumption). The frequency and dynamics of OHB were assessed by means of qualitative detection tests and quantification in the plasma. Resistance to HBV was determined by direct sequence analysis of the polymerase gene.

Results

Of the 29 HIV-infected individuals enrolled in the study, nine (31%) showed signs of OHB during the 100-week study period: three patients showed intermittent HB virus (HBV)-DNAemia, while six patients were HBV-DNA positive only at 16 weeks following HAART resumption. The HBV-DNA load invariably fell below the sensitivity of the quantitative test (10copies/mL). The HIV-related immuno-virologic profile and biochemical parameters, including hepatic transaminases, of patients with at least one HBV-DNA positive test result were not significant different from those of individuals who consistently tested negative for HBV-DNA. The only significant parameter was a lower median change (Δ1) in the CD4+/CD8+ ratio (p = 0.038) in occult HBV cases compared to non-occult cases, between the HAART re-introduction time point and baseline.

Conclusions

The intermittent nature of HBV-DNAemia poses a diagnostic challenge, but no association was found with transaminase levels at any time.
Literature
1.
go back to reference Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.PubMedCrossRef Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.PubMedCrossRef
2.
go back to reference Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58:383–8.PubMedCrossRef Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58:383–8.PubMedCrossRef
3.
go back to reference Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis. 2008;12:300–5.PubMedCrossRef Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis. 2008;12:300–5.PubMedCrossRef
4.
go back to reference Piroth L, Lafon ME, Binquet C, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis. 2008;31:1–5.CrossRef Piroth L, Lafon ME, Binquet C, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis. 2008;31:1–5.CrossRef
5.
go back to reference Fabris P, Biasin MR, Giordani MT, et al. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples. Curr HIV Res. 2008;6:173–9.PubMedCrossRef Fabris P, Biasin MR, Giordani MT, et al. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples. Curr HIV Res. 2008;6:173–9.PubMedCrossRef
6.
go back to reference Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis. 2003;188:571–7.PubMedCrossRef Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis. 2003;188:571–7.PubMedCrossRef
7.
go back to reference Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only marker. Eur J Clin Microbiol Infect Dis. 2005;24:492–4.PubMedCrossRef Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only marker. Eur J Clin Microbiol Infect Dis. 2005;24:492–4.PubMedCrossRef
8.
go back to reference Bloquel B, Jeulin H, Burty C, Letranchant L, Rabaud C, Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol. 2010;82:206–12.PubMedCrossRef Bloquel B, Jeulin H, Burty C, Letranchant L, Rabaud C, Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol. 2010;82:206–12.PubMedCrossRef
9.
go back to reference Schnepf N, Sellier P, Bendenoun M, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol. 2007;39:48–50.PubMedCrossRef Schnepf N, Sellier P, Bendenoun M, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol. 2007;39:48–50.PubMedCrossRef
10.
go back to reference Clark SJ, Creighton S, Horner M, et al. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS. 2006;17:67–9.PubMedCrossRef Clark SJ, Creighton S, Horner M, et al. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS. 2006;17:67–9.PubMedCrossRef
11.
go back to reference Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795–803.PubMedCrossRef Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795–803.PubMedCrossRef
12.
go back to reference Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445–9.PubMedCrossRef Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445–9.PubMedCrossRef
13.
go back to reference Morsica G, Bagaglio S, Cicconi P, et al. Viral interference between Hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr. 2009;51:574–81.PubMedCrossRef Morsica G, Bagaglio S, Cicconi P, et al. Viral interference between Hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr. 2009;51:574–81.PubMedCrossRef
14.
go back to reference Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36:681–6.PubMedCrossRef Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36:681–6.PubMedCrossRef
15.
go back to reference Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60.PubMedCrossRef Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60.PubMedCrossRef
16.
go back to reference Laguno M, Larrousse M, Blanco JL, et al. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients. AIDS Res Hum Retroviruses. 2008;24:547–53.PubMedCrossRef Laguno M, Larrousse M, Blanco JL, et al. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients. AIDS Res Hum Retroviruses. 2008;24:547–53.PubMedCrossRef
17.
go back to reference Allain JP, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology. 2009;49:1868–76.PubMedCrossRef Allain JP, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology. 2009;49:1868–76.PubMedCrossRef
18.
go back to reference Nebbia G, Garcia-Diaz A, Ayliffe U, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007;79:1464–71.PubMedCrossRef Nebbia G, Garcia-Diaz A, Ayliffe U, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007;79:1464–71.PubMedCrossRef
19.
go back to reference Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol. 2009;8:441–5.CrossRef Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol. 2009;8:441–5.CrossRef
Metadata
Title
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption
Authors
S. Bagaglio
G. Bianchi
A. Danise
L. Porrino
C. Uberti-Foppa
A. Lazzarin
A. Castagna
G. Morsica
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Infection / Issue 2/2011
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0093-9

Other articles of this Issue 2/2011

Infection 2/2011 Go to the issue